Recently, the Guangdong Provincial Health Commission and the Provincial Drug Administration jointly announced the list of designated medical institutions in the 4th batch of the “Hong Kong and Macau Pharmaceutical Device Connect”, and the Shenzhen Children's Hospital was successfully selected. The reporter learned yesterday from the Municipal Children's Hospital that future patients will have the opportunity to use clinically urgently needed imported drugs and medical devices that have already been listed in Hong Kong and Macao but have not yet been registered in the mainland. Of the newly approved medical institutions, there are 7 in Shenzhen, including Shenzhen Children's Hospital. “For families with sick children, the core value of this policy is to provide children with more diverse treatment options.” Ma Xiaopeng, director of the hospital, explained that the “Hong Kong and Macau Drug Access” policy has filled gaps in the treatment of some serious, rare, or complex diseases. In Shenzhen, you can apply for the use of international cutting-edge pharmaceutical devices that have been verified to be effective in Hong Kong and Macao, opening up a “life channel” for some “unusable” patients. The introduction of internationally synchronized targeted drugs, biologics, and advanced devices has given doctors more advanced “weapons” when dealing with complex diseases such as tumors, nerves, blood, and congenital malformations, which can help implement individualized treatment plans and improve efficacy and quality of life. (Shenzhen Special Administrative Region Newspaper)

Recently, the Guangdong Provincial Health Commission and the Provincial Drug Administration jointly announced the list of designated medical institutions in the 4th batch of the “Hong Kong and Macau Pharmaceutical Device Connect”, and the Shenzhen Children's Hospital was successfully selected. The reporter learned yesterday from the Municipal Children's Hospital that future patients will have the opportunity to use clinically urgently needed imported drugs and medical devices that have already been listed in Hong Kong and Macao but have not yet been registered in the mainland. Of the newly approved medical institutions, there are 7 in Shenzhen, including Shenzhen Children's Hospital. “For families with sick children, the core value of this policy is to provide children with more diverse treatment options.” Ma Xiaopeng, director of the hospital, explained that the “Hong Kong and Macau Drug Access” policy has filled gaps in the treatment of some serious, rare, or complex diseases. In Shenzhen, you can apply for the use of international cutting-edge pharmaceutical devices that have been verified to be effective in Hong Kong and Macao, opening up a “life channel” for some “unusable” patients. The introduction of internationally synchronized targeted drugs, biologics, and advanced devices has given doctors more advanced “weapons” when dealing with complex diseases such as tumors, nerves, blood, and congenital malformations, which can help implement individualized treatment plans and improve efficacy and quality of life. (Shenzhen Special Administrative Region Newspaper)